Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
October 09 2024 - 8:30AM
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the
“Company”), a specialty pharmaceutical company focused on the
development and commercialization of therapies for the treatment of
neurologic diseases, today announced that Alexandra MacLean, M.D.,
Chief Executive Officer of Avenue Therapeutics, will participate in
a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on
Tuesday, October 15, 2024 at 1:30 PM ET.
The fireside chat will be available to
registered attendees. Investors may sign-up or log-in to the
conference here.
About Avenue TherapeuticsAvenue
Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical
company focused on the development and commercialization of
therapies for the treatment of neurologic diseases. It is currently
developing three assets including AJ201, a first-in-class asset for
spinal and bulbar muscular atrophy, BAER-101, an oral small
molecule selective GABAA α2, α3 receptor positive allosteric
modulator for CNS diseases, and IV tramadol for the management of
acute postoperative pain in adults in a medically supervised
healthcare setting. Avenue is headquartered in Miami, FL and was
founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more
information, visit www.avenuetx.com.
Contact: Jaclyn Jaffe Avenue Therapeutics, Inc.
(781) 652-4500ir@avenuetx.com
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Dec 2023 to Dec 2024